Waterford has established itself as a suitable base for pharmaceutical manufacturing following the success of Genzyme.

The IDA is in talks with a major international pharmaceutical about making an investment of between €500 million and €1 billion in Waterford. The tal(...)

The market for MS drugs will grow to $20.2 billion a year by 2017, according to a 2011 report by GlobalData, a London- based research company.

Sanofi failed to win US regulatory approval for its multiple sclerosis drug Lemtrada, denting the company’s ambitions of capturing a larger share of t(...)

Blood pressure checks in the boardroom, cancer screening in the canteen, Reiki in reception – savvy Irish bosses are realising that money spent on a h(...)

Smile as you dial: Nev Wilshire, the hands-on-manager, with Kayleigh, one of the staff, in the fly-on-the-wall series The Call Centre. Photograph: BBC

Does your work make you happy? Are your colleagues content? Does it matter a whit? Employment experts from around Europe who converged in Dublin this (...)

Elan and Royalty Pharma have dismissed each others’ valuations of future sales of Tysabri, Elan’s multiple sclerosis drug sold to its partner Biogen Idec this year in a deal that freed cash and set Elan on an acquisition trail for new investments.

The bitter battle for Elan intensified yesterday after private equity group Royalty Pharma raised its all-cash offer for the Irish-based speciality dr(...)

Shareholders approved Elan’s  $1 billion share buyback this morning. Photograph: Alan Betson / THE IRISH TIMES

Irish drugmaker Elan got strong approval from shareholders for a $1 billion (€766,000) share buyback as it seeks to keep them on side and stave(...)

Sanofi wins backing for multiple sclerosis tablet. Photograph: Reuters

Sanofi won backing from a European advisory panel for its first multiple sclerosis therapy, the tablet Aubagio, a step forward in the French dr(...)